Targets › SELE
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout May 2027.
Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. (UniProt, P16581)
Open in Phaseline: the race on SELE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Uproleselan Selectin E antagonist | SELE | Phase 2 | Acute Myeloid Leukemia; Acute Myeloid Leukemia Post Cytotoxic Therapy | May 2027 |
Acute Myeloid Leukemia (1) Acute Myeloid Leukemia Post Cytotoxic Therapy (1)
mixed (1)
National Cancer Institute (NCI) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.